特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
595459

EpiCast Report:慢性腎疾患 (CKD) の疫学的予測

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

出版日: | 発行: GlobalData | ページ情報: 英文 32 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
EpiCast Report:慢性腎疾患 (CKD) の疫学的予測
出版日: 2017年12月01日
発行: GlobalData
ページ情報: 英文 32 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本) における、慢性腎疾患 (CKD、慢性腎不全) の市場動向や今後の見通しについて分析し、現在の有病者数や発症状況 (年齢別・男女別など)、今後10年間の有病件数の予測値などを調査しております。

第1章 目次

第2章 慢性腎疾患 (CKD):エグゼクティブ・サマリー

第3章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
  • 世界各国での過去の傾向
  • 予測手法
    • 情報源
    • 予測の前提条件と手法
  • 慢性腎疾患 (CKD):疫学的予測 (今後11年間分)
    • CKDの有病者総数:病期 (ステージ) I~IV
    • 年齢別の有病者数:病期I~IV
    • 男女別の有病者数:病期I~IV
    • 病期別の有病者数
    • CKDの受診済み有病者数:病期I~V
    • CKDの受診済み有病者数:病期別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

目次
Product Code: GDHCER175-17

Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time (NIH, 2010). As the disease progresses, the symptoms worsen, eventually leading to kidney failure (NIH, 2010). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.

CKD affects people of all ages, but the risk is higher in those ages 65 years and older. Globally, the estimated prevalence of CKD is around 7% in people over the age of 30 years (Zhang and Rothenbacher, 2008). In addition, CKD is more common in women thanmen, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin.

In the 7MM, our epidemiologists forecast the diagnosed prevalent cases of CKD, Stages I-V, to increase from around 25.7 million cases in 2016 to over 28.3 million cases in 2026, at an Annual Growth Rate (AGR) of almost 1%. The UK will have the highest number of diagnosed cases of CKD throughout the forecast period.

The report "EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends of CKD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.

Scope

  • The Chronic Kidney Disease EpiCast Report provides an overview of the risk factors and global trends of chronic kidney disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.
  • The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Kidney Disease EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease treatment market.
  • Quantify patient populations in the chronic kidney disease market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic kidney disease therapeutics in each of the markets covered.
  • Understand magnitude of chronic kidney disease.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Chronic Kidney Disease: Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 9
    • 3.4.1 Sources 10
    • 3.4.2 Forecast Assumptions and Methods 14
  • 3.5 Epidemiological Forecast for CKD (2016-2026) 20
    • 3.5.1 Total Prevalent Cases of CKD, Stages I-IV 20
    • 3.5.2 Age-Specific Total Prevalent Cases of CKD, Stages I-IV 20
    • 3.5.3 Sex-Specific Total Prevalent Cases of CKD, Stages I-IV 21
    • 3.5.4 Total Prevalent Cases of CKD by Stage 22
    • 3.5.5 Diagnosed Prevalent Cases of CKD, Stages I-V 23
    • 3.5.6 Diagnosed Prevalent Cases of CKD by Stage 24
  • 3.6 Discussion 25
    • 3.6.1 Epidemiological Forecast Insight 25
    • 3.6.2 Limitations of the Analysis 26
    • 3.6.3 Strengths of the Analysis 26

4 Appendix 27

  • 4.1 Bibliography 27
  • 4.2 About the Authors 29
    • 4.2.1 Epidemiologists 29
    • 4.2.2 Reviewers 29
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 30
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 31
  • 4.3 About GlobalData 32
  • 4.4 Contact Us 32
  • 4.5 Disclaimer 32

List of Tables

  • Table 1: KDIGO Classification of CKD 7
  • Table 2: Risk Factors and Comorbidities for CKD 8
  • Table 3: 7MM, Total Prevalent Cases of CKD, Stages I-IV, Both Sexes, Ages ≥20 Years, N, Selected Years from 2016-2026 20
  • Table 4: 7MM, Diagnosed Prevalent Cases of CKD, Stages I-V, Both Sexes, Ages ≥20 Years, N, Selected Years from 2016-2026 24

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of CKD, Stages I-V, Both Sexes, Ages ≥20 Years, N, 2016 and 2026 5
  • Figure 2: 7MM, Age-Standardized Total Prevalence of CKD, Stages I-IV, Ages ≥20 Years, 2016 9
  • Figure 3: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD Stages I-IV 10
  • Figure 4: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD by Stage 11
  • Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD Stages I-IV 12
  • Figure 6: 7MM, Sources Used to Forecast the Number of CKD Cases on Dialysis 13
  • Figure 7: 7MM, Sources Used to Forecast the Number of New Kidney Transplants 14
  • Figure 8: 7MM, Age-Specific Total Prevalent Cases of CKD, Stages I-IV, Both Sexes, Ages ≥20 Years, N, 2016 21
  • Figure 9: 7MM, Sex-Specific Total Prevalent Cases of CKD, Stages I-IV, Both Sexes, Ages ≥20 Years, N, 2016 22
  • Figure 10: 7MM, Total Prevalent Cases of CKD by Stage, Both Sexes, Ages ≥20 Years, N, 2016 23
  • Figure 11: 7MM, Diagnosed Prevalent Cases of CKD by Stage, Both Sexes, Ages ≥20 Years, N, 2016 25
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.